Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Torres, O.
Right arrow Articles by Fernandez, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Torres, O.
Right arrow Articles by Fernandez, J. C.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 18, Issue 3 393-397, Copyright © 1995 by American Diabetes Association


ARTICLES

Treatment of hypercholesterolemia in NIDDM with policosanol

O Torres, AJ Agramonte, J Illnait, R Mas Ferreiro, L Fernandez and JC Fernandez
Julio Trigo Hospital, Havana, Cuba.

OBJECTIVE--To determine whether elevated levels of cholesterol and low-density lipoprotein (LDL) cholesterol in non-insulin-dependent diabetes mellitus (NIDDM) patients could be decreased by policosanol, a new cholesterol-lowering drug. NIDDM predisposes patients to coronary artery disease (CAD) through the direct action of hyperglycemia on the arteries as well as the dyslipidemia induced by NIDDM. RESEARCH DESIGN AND METHODS--This double-blind placebo-controlled trial was performed in 29 patients with NIDDM and hypercholesterolemia. After stable glycemic control was achieved by diet and/or oral hypoglycemic drugs, patients were instructed to follow a cholesterol-lowering diet for 6 weeks. Patients who met entry criteria received, under double-blind conditions, policosanol (5 mg) or placebo tablets twice a day for 12 weeks. RESULTS--Policosanol (10 mg/day) significantly reduced total cholesterol by 17.5% and LDL cholesterol by 21.8% compared with baseline and placebo. Furthermore, high-density lipoprotein (HDL) cholesterol was raised by 11.3% (not significant), and triglycerides showed a statistically nonsignificant decrease of 6.6%. These changes in lipid profile were similar to those induced by policosanol in nondiabetic patients with type II hyperlipoproteinemia. CONCLUSIONS--Glycemic control was unaffected by treatment. No clinically or biochemically adverse effects attributable to treatment were observed. Only one patient (placebo) withdrew from the trial because of an adverse experience (erythema). We concluded that policosanol is effective and safe in patients with NIDDM and hypercholesterolemia.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
ANGIOLOGYHome page
J. Illnait, G. Castano, E. Alvarez, L. Fernandez, R. Mas, S. Mendoza, and R. Gamez
Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study
Angiology, July 1, 2008; 59(3): 269 - 277.
[Abstract] [PDF]


Home page
Am. J. Clin. Nutr.Home page
M. F Dulin, L. F Hatcher, H. C Sasser, and T. A Barringer
Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial
Am. J. Clinical Nutrition, December 1, 2006; 84(6): 1543 - 1548.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
G. Castano, R. Mas, R. Gamez, L. Fernandez, and J. Illnait
Effects of Policosanol and Ticlopidine in Patients with Intermittent Claudication: A Double-Blinded Pilot Comparative Study
Angiology, July 1, 2004; 55(4): 361 - 371.
[Abstract] [PDF]


Home page
Exp. Biol. Med.Home page
J. L. Hargrove, P. Greenspan, and D. K. Hartle
Nutritional Significance and Metabolism of Very Long Chain Fatty Alcohols and Acids from Dietary Waxes
Experimental Biology and Medicine, March 1, 2004; 229(3): 215 - 226.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
G. Castano, R. Mas, L. Fernandez, R. Gamez, and J. Illnait
Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study
Angiology, January 1, 2003; 54(1): 25 - 38.
[Abstract] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
G. Castaño, R. Más, J.C. Fernández, J. Illnait, L. Fernández, and E. Alvarez
Effects of Policosanol in Older Patients With Type II Hypercholesterolemia and High Coronary Risk
J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2001; 56(3): 186M - 193.
[Abstract] [Full Text]


Home page
ANGIOLOGYHome page
G. Castano, R. M. Ferreiro, L. Fernandez, R. Gamez, J. Illnait, and J. C. Fernandez
A Long-Term Study of Policosanol in the Treatment of Intermittent Claudication
Angiology, February 1, 2001; 52(2): 115 - 125.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
G. Castano, R. Mas, J. Roca, L. Fernandez, J. Illnait, J. C. Fernandez, E. Selman, and R. Mas
A Double-Blind, Placebo-Controlled Study of the Effects of Policosanol in Patients with Intermittent Claudication
Angiology, February 1, 1999; 50(2): 123 - 130.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1995 by the American Diabetes Association.